PCSK9 through non-lipid pathways in the pathogenesis of atheroscle-rosis:a review of progress in research
10.12092/j.issn.1009-2501.2025.10.012
- VernacularTitle:PCSK9通过非血脂途径致动脉粥样硬化的研究进展
- Author:
Dongze LI
1
;
Jiyi ZHAO
1
Author Information
1. 哈尔滨医科大学附属第一医院心内科,哈尔滨 150001,黑龙江
- Publication Type:Journal Article
- Keywords:
proprotein convertase subtilisin/KEX-IN type 9;
atherosclerotic cardiovascular disease;
PCSK9 inhibitors
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(10):1400-1407
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein convertase subtilisin/KEXIN type 9(PCSK9)is the ninth member of the pro pro-tein convertase family and released into the blood-stream.It reduces the availability of low-density li-poprotein receptors and leads to the accumulation of low-density lipoprotein cholesterol in plasma,thereby promoting the development of atheroscle-rotic plaques and thrombotic events.In addition to its classical pathway,recent studies have demon-strated multiple non-classical pathways by which PCSK9 influences the development of atherosclero-sis-related diseases,including participation in in-flammatory responses,regulation of autophagy and cell apoptosis,promotion of platelet activation and thrombus formation,etc.This article provides an overview of the latest progress in the molecular mechanism by which PCSK9 affects atherosclerotic diseases through non-lipid-dependent pathways.
